Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:02 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD)
NCT03170232 · GlaxoSmithKline · PHASE2 · terminated · last registry update 2020-07-31 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Terminated based on lack of efficacy seen in participants taking danirixin in dose ranging study and Sponsor decision to stop development of danirixin for COPD” | – | Registry record, GlaxoSmithKline |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CXCR2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-06-02Results posted on the registry: Dompé Farmaceutici S.p.A, paclitaxel + Reparixin (NCT02370238)
- 2021-05-14Also stopped (terminated): Dompé Farmaceutici S.p.A, Reparixin (NCT01861054)
- 2021-05-07Phase 3 first posted: Dompé Farmaceutici S.p.A, Reparixin (NCT04878055)
- 2021-04-19Results posted on the registry: Dompé Farmaceutici S.p.A, Paclitaxel+Reparixin (NCT02001974)
- 2021-03-29Also stopped (terminated): GlaxoSmithKline, Danirixin + Placebo (NCT03250689)
- 2021-03-25Results posted on the registry: Dompé Farmaceutici S.p.A, Reparixin (NCT01861054)
- 2021-03-12Phase 3 first posted: Dompé Farmaceutici S.p.A, Reparixin + Standard of care (NCT04794803)
- 2021-03-11Results posted on the registry: Dompé Farmaceutici S.p.A, Reparixin (NCT01220856)
- 2021-01-12Results posted on the registry: Dompé Farmaceutici S.p.A, Ladarixin + Placebo (NCT02814838)
- 2020-11-30Also stopped (terminated): GlaxoSmithKline, Danirixin 15 mg FBE + Danirixin 50 mg FBE (NCT02927431)
- 2020-10-30Also stopped (terminated): GlaxoSmithKline, SB-656933 (NCT00748410)
- 2020-04-14Results posted on the registry: Dompé Farmaceutici S.p.A, Reparixin continuous infusion + reparixin intermittent infusion (NCT00248040)
- 2019-12-18Results posted on the registry: Dompé Farmaceutici S.p.A, Reparixin + Placebo (NCT01817959)
- 2019-11-29Results posted on the registry: GlaxoSmithKline, Danirixin + Danirixin matching placebo (NCT03034967)
- 2019-11-08Results posted on the registry: GlaxoSmithKline, Danirixin + Placebo (NCT03250689)
- 2019-10-09Results posted on the registry: Dompé Farmaceutici S.p.A, Reparixin + Placebo (NCT01967888)
- 2019-08-28Results posted on the registry: GlaxoSmithKline, Danirixin + Omeprazole (NCT03457727)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision